WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine 01 July 2022
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron 25 June 2022
Pfizer to invest $120 million to produce COVID-19 oral treatment in the U.S. 08 June 2022
Pfizer 'aunches 'An Accord for a Healthier World' to improve health equity for 1.2 billion people living in 45 lower-income countries 25 May 2022
Pfizer to acquire Biohaven Pharmaceuticals 10 May 2022
Pfizer shares top-line results from Phase 2/3 EPIC-PEP study of PAXLOVID™ for post-exposure prophylactic use 02 May 2022
Pfizer and Biohaven's VYDURA® (rimegepant) granted first ever marketing authorization by European Commission for both acute treatment of migraine and prophylaxis of episodic migraine 27 April 2022
Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates 07 April 2022
Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries 22 March 2022
Pfizer and BioNTech aubmit for U.S. Emergency Use Authorization of an additional booster dose of their COVID-19 vaccine for older adults 17 March 2022
Pfizer updates company position in Russia 14 March 2022
Valneva and Pfizer report further positive Phase 2 data for Lyme disease vaccine candidate 04 February 2022
Pfizer receives CHMP positive opinion for novel COVID-19 oral treatment 01 February 2022
Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age 26 January 2022
Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant 24 January 2022
Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant 18 January 2022
Pfizer and BioNTech receive U.S. FDA Emergency Use Authorization of COVID-19 vaccine booster for individuals 12 years of age and older 04 January 2022
Pfizer and BioNTech provide update on Omicron variant 08 December 2021
AWS helps Pfizer accelerate drug development and clinical manufacturing 02 December 2021
Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19 18 November 2021
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.